STOCK TITAN

Neuronetics (STIM) Stock Price, News & Analysis

STIM NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
102 252 sessions, November 14, 2025 to November 16, 2026
Largest daily move
+47% close of August 11, 2026
1-year change
-37.2% closing prices, November 14, 2025 to November 16, 2026
1-month change
-33.7% closing prices, October 16, 2026 to November 16, 2026

Company Description

Neuronetics, Inc. (NASDAQ: STIM) is a commercial stage medical technology and healthcare company in the surgical and medical instrument manufacturing industry. According to company disclosures, Neuronetics focuses on designing, developing, and marketing products intended to improve the quality of life for patients who suffer from neurohealth and psychiatric disorders. The company describes a strategic vision of transforming the lives of patients whenever and wherever they need help, using what it characterizes as leading neurohealth therapies.

Neuronetics is closely associated with NeuroStar Advanced Therapy, a non-drug, noninvasive, office-based treatment that uses transcranial magnetic stimulation (TMS). Neuronetics, Inc.'s NeuroStar Advanced Therapy System creates pulsed, MRI-strength magnetic fields designed to stimulate specific areas of the brain associated with mood. The company positions NeuroStar Advanced Therapy as a non-invasive therapeutic alternative for patients with major depressive disorder (MDD) when traditional medication has not provided satisfactory improvement.

Neuronetics reports that NeuroStar Advanced Therapy is cleared by the U.S. Food and Drug Administration for several indications. These include treatment of depressive episodes in adults with MDD who have not achieved satisfactory improvement from previous antidepressant medication in the current episode, decreasing anxiety symptoms in adult patients with MDD who may exhibit comorbid anxiety symptoms (anxious depression), and use as an adjunct for adults with obsessive-compulsive disorder. The therapy is also cleared as a first-line adjunct for the treatment of MDD in adolescent patients aged 15–21. These regulatory clearances are central to the company’s positioning in the neurohealth and mental health treatment market.

In addition to manufacturing and selling the NeuroStar Advanced Therapy System and associated treatment sessions, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States. Company press releases explain that these centers offer NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. Greenbrook treatment centers also offer SPRAVATO (esketamine) Nasal Spray, which Neuronetics describes as a prescription medicine indicated for treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant, and for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant. Neuronetics reports that Greenbrook has delivered more than one million treatments to tens of thousands of patients struggling with depression, based on the ranges disclosed in its news releases.

The company repeatedly characterizes itself as a global leader in neuroscience and emphasizes that it delivers in-office treatments through NeuroStar Advanced Therapy that can improve quality of life for people suffering from neurohealth conditions when traditional medication has not helped. Neuronetics highlights that NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, citing millions of treatment sessions delivered and what it describes as the largest clinical data set and the world’s largest depression outcomes registry for a TMS treatment system for depression. These statements underscore the company’s focus on evidence-based, device-driven mental health therapies.

Neuronetics’ business model, as described in its press releases and SEC filings, combines medical device manufacturing with healthcare service delivery. Revenue sources identified by the company include sales of NeuroStar Advanced Therapy Systems, treatment sessions, and clinic revenue generated by Greenbrook treatment centers. The company’s SEC filings further describe it as vertically integrated following its acquisition of Greenbrook TMS Inc., with U.S. clinic revenue reported as a distinct category alongside system and treatment session revenue. This integration links the company’s device platform with a network of treatment centers that use those devices in clinical practice.

From a regulatory and capital markets perspective, Neuronetics’ common stock trades on The Nasdaq Global Market under the symbol STIM, as noted in its Form 8-K filings. These filings also indicate that the company uses credit facilities and equity offerings to support its operations and growth initiatives. For example, Neuronetics has described amendments to its credit agreement with Perceptive Credit Holdings IV, LP that provide additional borrowing capacity and adjust liquidity requirements, and it has disclosed the use of at-the-market equity offerings to raise capital for general corporate purposes.

Neuronetics is headquartered in Malvern, Pennsylvania, according to its SEC filings, which list Malvern and the associated ZIP code as the location of its principal offices. The company’s disclosures and press releases consistently emphasize a belief that mental health is as important as physical health and describe a commitment to expanding access to advanced mental health therapies. This includes working with payors and health policy stakeholders. Neuronetics notes that it is the only TMS company in its industry with a dedicated health policy team that partners with providers and payors to advocate for health policy updates, including coverage decisions for TMS therapy.

The company’s communications also highlight payer coverage milestones and partnerships that are relevant to its operating environment. For example, Neuronetics has announced expanded coverage for NeuroStar TMS therapy by New York State Medicaid for adults with MDD and by TRICARE West for adolescents aged 15 and older. It has also described exclusive agreements, such as a three-year collaboration with Elite DNA Behavioral Health, under which Neuronetics becomes the sole provider of TMS devices across that network’s locations and uses the Greenbrook platform to provide fee-based operational and patient-support services.

Neuronetics’ SEC filings and press releases further indicate that the company monitors and reports on the number of patients treated and treatment sessions delivered using NeuroStar TMS. Milestones cited include hundreds of thousands of global patients and several million treatment sessions. The company also references real-world clinical data drawn from its NeuroStar outcomes databases, including data published in peer-reviewed journals on the effectiveness of NeuroStar TMS in adolescents and young adults with MDD.

For investors and analysts evaluating STIM stock, Neuronetics represents a medical technology issuer at the intersection of device manufacturing and behavioral health services. Its disclosures emphasize the importance of regulatory clearances, payer coverage, clinical evidence, and the integration of its device platform with owned and affiliated treatment centers. The company’s SEC filings, including periodic reports and current reports on Form 8-K, provide additional detail on its financial performance, capital structure, and material agreements.

Business segments and activities

Based on the company’s own categorizations in its financial reporting, Neuronetics’ activities can be viewed across several primary areas:

  • NeuroStar Advanced Therapy System: Design, development, and sale of the TMS system used to deliver NeuroStar Advanced Therapy in clinical settings.
  • Treatment sessions: Sale of treatment sessions associated with the NeuroStar system, as reported in its U.S. revenues by product category.
  • Clinic revenue: Revenue generated by Greenbrook treatment centers in the United States, which provide NeuroStar TMS, SPRAVATO, and other modalities for MDD and other mental health disorders.
  • Health policy and payer engagement: Activities by a dedicated health policy team that works with providers and payors to support coverage and reimbursement for TMS therapy.

Regulatory and clinical context

Neuronetics’ disclosures emphasize that the NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for specific indications in adult and adolescent populations. The company also references a large outcomes registry and clinical data sets that support the use of NeuroStar TMS in depression, including adolescents and young adults. These elements are central to how Neuronetics presents its role in the mental health treatment landscape.

Stock and corporate information

Neuronetics’ common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Global Market under the ticker symbol STIM, as confirmed in multiple Form 8-K filings. These filings also identify Malvern, Pennsylvania as the location of the company’s principal offices. Neuronetics uses current reports on Form 8-K to communicate material events, such as financial results, executive appointments, credit facility amendments, and leadership transition plans.

Stock Performance

$1.27
+1.60%
+0.02
Pre-marketLast updated: November 17, 2026 at 08:02
-37.2%
Performance 1 year
$122.5M

Neuronetics (STIM) closed at $1.25 on November 16, 2026. Over the past 12 months, the price has lost 37.2%.

See what a $1,000 investment in STIM would be worth today

Average down calculator for STIM

STIM Metrics & Rankings

Price returns through November 16, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Insider Radar

Net Sellers
90-Day Summary
58,000
Shares Bought
3,335,411
Shares Sold
7
Transactions
Most Recent Transaction
Chernett Jorey (10% Owner) sold 2,187,051 shares @ $1.15 on November 13, 2026

Insider selling at Neuronetics over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Neuronetics generated $149.2M in revenue in FY2025, retaining a 48.5% gross margin, operating income reached -$31.4M (-21.1% operating margin), and net income was -$39.0M, reflecting a -26.2% net profit margin. Diluted earnings per share stood at -$0.59. The company generated -$20.4M in operating cash flow. The current ratio was 2.02, measuring current assets divided by current liabilities.

$149.2M
Revenue (FY2025)
-$39.0M
Net Income (FY2025)
-$20.4M
Operating Cash Flow

Upcoming Events

NOV
30
November 30, 2026 Financial

Perceptive amendment deadline

Amendment to Perceptive credit agreement automatically terminates unless conditions (including $15M prepayment) met or waived.
NOV
30
November 30, 2026 Financial

Amendment termination

Credit amendment automatically terminates if conditions not satisfied or waived by Nov 30, 2026; affects covenants.
DEC
10
December 10, 2026 Financial

Underwriter option expiration

30-day underwriter option to purchase up to an additional 15% of offered shares will expire if not exercised by this date.
DEC
10
December 10, 2026 Financial

Underwriter option expiry

30-day underwriter option to purchase up to 2,812,500 additional shares expires around Dec 10, 2026.
APR
29
April 29, 2027 - April 29, 2030 Corporate

RSU vesting schedule

122,400 RSUs granted Apr 29, 2026 vest in thirds on service anniversaries; vesting begins 2027-04-29 through 2030-04-29.
JUN
01
June 1, 2027 - June 1, 2030 Corporate

Inducement RSU vesting schedule

200,000 inducement RSUs vest in four equal annual installments starting 2027-06-01 to 2030-06-01 under Nasdaq rule 5635(c)(4).

Neuronetics has 6 upcoming scheduled events. The next event, "Perceptive amendment deadline", is scheduled for November 30, 2026 (in 13 days). 4 of them are financing or capital events, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the STIM stock price.

Short Interest History

Last 12 Months

Short interest in Neuronetics (STIM) currently stands at 6.7 million shares, down 7.6% from the previous reporting period, representing 19.5% of the float. Since November 2025, short interest has increased by 11.0%.

Days to Cover History

Last 12 Months

Days to cover for Neuronetics (STIM) currently stands at 9.9 days. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 377.8%. Across the settlements charted above, it has ranged from 1.6 to 12.2 days.

STIM Company Profile & Sector Positioning

Neuronetics (STIM) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing STIM often look at related companies in the same sector, including TriSalus Life Sciences, Inc. (TLSI), Inogen Inc (INGN), Quanterix Corporation (QTRX), Pulmonx Corporation (LUNG), and MaxCyte, Inc. (MXCT). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate STIM's relative position within its industry.

Frequently Asked Questions

The current stock price of Neuronetics (STIM) is $1.27 in pre-market trading as of November 17, 2026.

The market cap of Neuronetics (STIM) is approximately $122.5M. Learn more about what market capitalization means .

The FY2025 revenue of Neuronetics (STIM) is $149.2M, from its most recent completed fiscal year.

The FY2025 net income of Neuronetics (STIM) is -$39.0M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Neuronetics (STIM) is -$0.59 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Neuronetics (STIM) is -$20.4M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Neuronetics (STIM) is -26.2% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Neuronetics (STIM) is -21.1% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Neuronetics (STIM) is 48.5% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Neuronetics (STIM), current assets divided by current liabilities, was 2.02 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Neuronetics (STIM) is $72.3M for FY2025, its most recent completed fiscal year.

The operating income of Neuronetics (STIM) is -$31.4M for FY2025, its most recent completed fiscal year. Learn about operating income.

Neuronetics, Inc. is a commercial stage medical technology and healthcare company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth and psychiatric disorders. Its primary platform is the NeuroStar Advanced Therapy System, a non-drug, noninvasive transcranial magnetic stimulation (TMS) treatment.

According to Neuronetics, the NeuroStar Advanced Therapy System delivers transcranial magnetic stimulation, creating pulsed, MRI-strength magnetic fields that induce electrical currents intended to stimulate specific brain regions associated with mood. It is used as an office-based, non-invasive treatment for certain patients with major depressive disorder and related indications.

Company disclosures state that NeuroStar Advanced Therapy is cleared by the U.S. Food and Drug Administration for adults with major depressive disorder who have not achieved satisfactory improvement from prior antidepressant medication, to decrease anxiety symptoms in adult patients with MDD who may exhibit comorbid anxiety symptoms, as an adjunct for adults with obsessive-compulsive disorder, and as a first-line adjunct for MDD in adolescent patients aged 15–21.

Neuronetics’ financial reporting identifies revenue from sales of NeuroStar Advanced Therapy Systems, associated treatment sessions, and clinic revenue from Greenbrook treatment centers in the United States. These are presented as separate categories in its U.S. revenues by product category.

Neuronetics’ Form 8-K filings list Malvern, Pennsylvania, along with a corresponding ZIP code, as the location of the company’s principal offices.

Neuronetics’ common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Global Market under the ticker symbol STIM, as noted in its SEC filings.

In its press releases, Neuronetics describes itself as a global leader in neuroscience and states that NeuroStar Advanced Therapy is the leading TMS treatment for major depressive disorder in adults, supported by millions of treatments delivered and what it identifies as the largest clinical data set and outcomes registry for a TMS treatment system for depression.

Yes. Neuronetics states that it is the only TMS company in its industry with a dedicated health policy team that partners with providers and payors to advocate for health policy updates. The company has highlighted coverage expansions for NeuroStar TMS by New York State Medicaid and TRICARE West for specific patient groups.

Neuronetics’ SEC filings, including Forms 8-K, provide information on material events such as quarterly financial results, amendments to credit agreements, executive appointments and leadership transitions, investor presentations, and details about its stock listing on The Nasdaq Global Market under the symbol STIM.